Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -8.09%4.69B | -7.74%3.14B | -11.08%1.46B | -8.90%6.25B | -8.25%5.1B | -7.28%3.4B | -3.47%1.64B | 5.84%6.86B | 4.71%5.56B | 6.17%3.67B |
| Operating income | -8.09%4.69B | -7.74%3.14B | -11.08%1.46B | -8.90%6.25B | -8.25%5.1B | -7.28%3.4B | -3.47%1.64B | 5.84%6.86B | 4.71%5.56B | 6.17%3.67B |
| Cost of sales | 8.03%-2.28B | 7.58%-1.52B | 10.16%-716M | 8.93%-3.1B | 9.13%-2.48B | 8.39%-1.65B | 6.01%-797M | -5.10%-3.4B | -4.60%-2.73B | -5.76%-1.8B |
| Operating expenses | 8.03%-2.28B | 7.58%-1.52B | 10.16%-716M | 8.93%-3.1B | 9.13%-2.48B | 8.39%-1.65B | 6.01%-797M | -5.10%-3.4B | -4.60%-2.73B | -5.76%-1.8B |
| Gross profit | -8.15%2.41B | -7.88%1.61B | -11.94%745M | -8.86%3.15B | -7.40%2.63B | -6.21%1.75B | -0.94%846M | 6.57%3.45B | 4.80%2.84B | 6.56%1.87B |
| Selling expenses | 6.00%-1.52B | 4.83%-749M | 5.40%-438M | 5.58%-1.63B | 2.06%-1.62B | 5.64%-787M | 0.64%-463M | -2.56%-1.72B | -3.71%-1.65B | -3.47%-834M |
| Administrative expenses | ---- | 7.79%-225M | ---- | -1.49%-477M | ---- | -4.27%-244M | ---- | -6.33%-470M | ---- | -5.41%-234M |
| Special items of operating profit | -10.98%73M | -34.15%27M | -4.00%24M | 96.30%53M | 0.00%82M | -10.87%41M | -16.67%25M | -80.71%27M | -22.64%82M | -25.81%46M |
| Operating profit | -11.55%965M | -12.48%666M | -18.87%331M | -14.82%1.1B | -13.89%1.09B | -9.94%761M | -2.39%408M | 2.30%1.29B | 3.85%1.27B | 7.51%845M |
| Financing income | -91.30%2M | -32.43%25M | -71.43%4M | 6.45%66M | 475.00%23M | 32.14%37M | 600.00%14M | 58.97%62M | -55.56%4M | 40.00%28M |
| Financing cost | ---- | -29.41%-22M | ---- | 32.69%-35M | ---- | 34.62%-17M | ---- | -33.33%-52M | ---- | -116.67%-26M |
| Share of profits of associates | 32.14%37M | 50.00%21M | 300.00%4M | 10.71%31M | 0.00%28M | -12.50%14M | -75.00%1M | 21.74%28M | 12.00%28M | 33.33%16M |
| Special items of earning before tax | 5.13%-37M | ---- | 84.62%-2M | ---- | -680.00%-39M | ---- | -225.00%-13M | ---- | 37.50%-5M | ---- |
| Earning before tax | -12.33%967M | -13.21%690M | -17.80%337M | -12.58%1.16B | -14.76%1.1B | -7.88%795M | -2.38%410M | 3.43%1.33B | 3.85%1.29B | 7.07%863M |
| Tax | -1.47%-345M | -8.68%-263M | 18.80%-95M | 8.28%-410M | 14.14%-340M | 11.36%-242M | -1.74%-117M | -33.83%-447M | -34.24%-396M | -64.46%-273M |
| After-tax profit from continuing operations | -18.48%622M | -22.78%427M | -17.41%242M | -14.77%750M | -15.03%763M | -6.27%553M | -3.93%293M | -7.27%880M | -5.57%898M | -7.81%590M |
| Earning after tax | -18.48%622M | -22.78%427M | -17.41%242M | -14.77%750M | -15.03%763M | -6.27%553M | -3.93%293M | -7.27%880M | -5.57%898M | -7.81%590M |
| Minority profit | 33.33%28M | 50.00%18M | 33.33%8M | -14.29%24M | -8.70%21M | -20.00%12M | -25.00%6M | -22.22%28M | -11.54%23M | 0.00%15M |
| Profit attributable to shareholders | -19.95%594M | -24.40%409M | -18.47%234M | -14.79%726M | -15.20%742M | -5.91%541M | -3.37%287M | -6.68%852M | -5.41%875M | -8.00%575M |
| Basic earnings per share | -24.39%0.031 | -14.57%0.0551 | -5.75%0.041 | -6.66%0.0645 | -8.03%0.0435 | |||||
| Diluted earnings per share | -24.57%0.0307 | -14.95%0.0546 | -6.00%0.0407 | -6.96%0.0642 | -8.26%0.0433 | |||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | PricewaterhouseCoopers | -- | -- | -- | PricewaterhouseCoopers | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.